Addex Pharmaceuticals discovers and develops allosteric modulators, a different kind of small molecule therapeutic agent. Allosteric modulation may offer more sophisticated ways to normalize biological signaling perturbed by disease compared to classical “orthosteric” agonist or antagonist drugs. Addex' goal is to grow into a world class pharmaceutical group by leveraging its expertise in this emerging class of drugs.
investors
In May 2007, Addex completed an initial public offering on the SWX Swiss Exchange, raising CHF137 million ($111 million / €83 million). Click here for stock quote & more.